Literature DB >> 7542695

Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470.

T Yazaki1, Y Takamiya, P C Costello, T Mineta, A G Menon, S D Rabkin, R L Martuza.   

Abstract

Meningiomas are relatively common (22%) vascular brain tumors. 3-11% of meningiomas are malignant, and defy currently available therapy. Inhibition of neovascularization is one potential strategy for treating these hypervascular tumors. Inhibition of tumor-induced angiogenesis by TNP-470 (previously termed AGM-1470), a synthetic analogue of fumagillin, was tested on the growth of human non-malignant and malignant meningiomas in nude mice. TNP-470 significantly inhibited tumor neovascularization and tumor growth of both non-malignant and malignant meningiomas. TNP-470 is now in human trial and should be tested for efficacy in treating malignant or recurrent aggressive meningiomas.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7542695     DOI： 10.1007/bf01058456

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  24 in total

1.  What is the evidence that tumors are angiogenesis dependent?

Authors:  J Folkman
Journal:  J Natl Cancer Inst       Date:  1990-01-03       Impact factor: 13.506

2.  Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent.

Authors:  M Kusaka; K Sudo; T Fujita; S Marui; F Itoh; D Ingber; J Folkman
Journal:  Biochem Biophys Res Commun       Date:  1991-02-14       Impact factor: 3.575

3.  Malignant transformation of recurrent meningioma with pulmonary metastases.

Authors:  D R LeMay; M N Bucci; S M Farhat
Journal:  Surg Neurol       Date:  1989-05

Review 4.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

5.  Implantation of human meningiomas into the subrenal capsule of the nude mouse. A model for studies of tumor growth.

Authors:  A Medhkour; M Van Roey; R A Sobel; H J Fingert; J Lee; R L Martuza
Journal:  J Neurosurg       Date:  1989-10       Impact factor: 5.115

6.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth.

Authors:  D Ingber; T Fujita; S Kishimoto; K Sudo; T Kanamaru; H Brem; J Folkman
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

7.  Growth of human schwannomas in the subrenal capsule of the nude mouse.

Authors:  J K Lee; T S Kim; E A Chiocca; A Medhkour; R L Martuza
Journal:  Neurosurgery       Date:  1990-04       Impact factor: 4.654

8.  AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo.

Authors:  Y Takamiya; H Brem; J Ojeifo; T Mineta; R L Martuza
Journal:  Neurosurgery       Date:  1994-05       Impact factor: 4.654

9.  Prediction of tumor doubling time in recurrent meningiomas. Cell kinetics studies with bromodeoxyuridine labeling.

Authors:  K G Cho; T Hoshino; T Nagashima; J A Murovic; C B Wilson
Journal:  J Neurosurg       Date:  1986-12       Impact factor: 5.115

10.  Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: six-day subrenal capsule assay.

Authors:  A E Bogden; W R Cobb; D J Lepage; P M Haskell; T A Gulkin; A Ward; D E Kelton; H J Esber
Journal:  Cancer       Date:  1981-07-01       Impact factor: 6.860
View more
  9 in total

1.  The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest.

Authors:  J R Yeh; R Mohan; C M Crews
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

Review 2.  Angiogenesis: possibilities for therapeutic interventions.

Authors:  W Wynendaele; A T van Oosterom; A Pawinski; E A de Bruijn; R A Maes
Journal:  Pharm World Sci       Date:  1998-12

Review 3.  Anti-angiogenic treatment strategies for malignant brain tumors.

Authors:  M Kirsch; G Schackert; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

4.  [Anti-angiogenesis: a new approach to tumor therapy?].

Authors:  D Schiefer; C Gottstein; V Diehl; A Engert
Journal:  Med Klin (Munich)       Date:  1999-10-15

Review 5.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

6.  Antitumor effect of TNP-470 is not associated to decrease of angiogenesis in an experimental malignant neuroectodermic tumor.

Authors:  C Morales; M Zurita; J Vaquero
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

7.  Development of patient-derived xenograft models from a spontaneously immortal low-grade meningioma cell line, KCI-MENG1.

Authors:  Sharon K Michelhaugh; Anthony R Guastella; Kaushik Varadarajan; Neil V Klinger; Prahlad Parajuli; Aamir Ahmad; Seema Sethi; Amro Aboukameel; Sam Kiousis; Ian M Zitron; Salah A Ebrahim; Lisa A Polin; Fazlul H Sarkar; Aliccia Bollig-Fischer; Sandeep Mittal
Journal:  J Transl Med       Date:  2015-07-15       Impact factor: 5.531

8.  Suppressive effect of the angiogenesis inhibitor TNP-470 on the development of carcinogen-induced hepatic nodules in rats.

Authors:  T Ikebe; T Yamamoto; S Kubo; K Hirohashi; H Kinoshita; K Kaneda; M Sakurai
Journal:  Jpn J Cancer Res       Date:  1998-02

Review 9.  Emerging Medical Treatments for Meningioma in the Molecular Era.

Authors:  Fares Nigim; Hiroaki Wakimoto; Ekkehard M Kasper; Linda Ackermans; Yasin Temel
Journal:  Biomedicines       Date:  2018-08-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.